Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication

• Autorzy: Walencka E , Sadowska B. , Rozalska S. , Hryniewicz W. , Rozalska B.
• Języki publikacji: EN

Abstrakty

EN

The aim was to study the activity of lysostaphin in monotherapy or in combination with oxacillin, towards biofilms built by clinical and reference S. aureus and S. epidermidis strains in the wells of microplate, in the chambers of a LabTekII chamber slide or on the polyethylene catheter. MICs of oxacillin and lysostaphin for planktonie bacteria were determined according to the standards of NCCLS. BIC (Biofilm Inhibitory Concentration) was estimated by the MTT assay. The integrity of biofilm treated with antimicrobials was also examined: by staining with FITC and laser scanning fluorescence confocal microscopy and visually by TTC reduction assay. Despite the fact that susceptibility of planktonie cultures of 25 staphylococcal strains to lysostaphin action was various, we have demonstrated the effectiveness of lysostaphin in the treatment of biofilm, built not only on the flat surface of the microplates but also on catheter's surface. The synergistic effect of subBIC lysostaphin+oxacillin was observed forMSSA and MRSA biofilms but not for 1474/01 hVISA strain. Also BICOXA for S. epidermidis RP12 and A4c strains, but not for 6756/99 MRSE biofilms was reduced when lysostaphin was simultaneously used.

Słowa kluczowe

EN

activity; bacterial biofilm; therapeutic agent; antibiotic; Staphylococcus epidermidis; Staphylococcus aureus; microbiology; monotherapy; lysostaphin; staphylococcal biofilm

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2005
• Tom: 54
• Numer: 3
• Opis fizyczny: p.191-200,fig.,ref.

Twórcy

autor

Walencka E

• University of Lodz, Banacha 12/16, 90-237 Lodz, Poland

autor

Sadowska B.

autor

Rozalska S.

autor

Hryniewicz W.

autor

Rozalska B.

Bibliografia

• Barequet I.S., G.J. Ben Simon, M. Safrin, D.E. Ohman and E. Kessler. 2004. Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis. Antimicrob. Agents Chemother. 48: 1881-1687.
• Boles B.R., M. Thoendel and RK. Singh. 2004. Self-generated diversity produces "insurance effects" in biofilm communities. PNAS. 101: 16630-16635.
• Boyle-Vavra S., R.B. Carey and R.S. Daum. 2001. Development of vancomycin and lysostaphin resistance in a methi-cillin-resistant Staphylococcus aureus isolate. J. Antimicrob. Chemother. 48: 617-625.
• Climo M.W., K. Ehlert and G.L. Archer. 2001. Mechanism and suppression of lysostaphin resistance in oxacillin-resis-tant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 1431-1437.
• Climo M.W., R.L. Patron, B.P. Goldstein and G.L. Archer. 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42: 1355-1360.
• Costa S.F., M.H. Miceli and E.J. Anaissie. 2004. Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? Lancet Inf. Dis. 4: 278-286.
• Dajcs J.J., B.A. Thibodeaux, D.O. Girgis, M.D. Shaffer, S.M. Delvisco and R.J. O'Callaghan. 2002. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest. Ophthalmol. Visual Sci. 43:3712-3716.
• Fux C.A., P. Stoodley, L. Hall-Stoodley and J.W. Costerton. 2003. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev. Anti-infect. Ther. 1: 667-683.
• Göz F. 2002. Staphylococcus and biofilms. Mol. Microbiol. 43: 1367-1378.
• Hall-Stoodley L., J.W. Costerton and P. Stoodley. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nature Rev. 2: 95-106.
• Johansen C, P. Falholt and L. Gram. 1997. Enzymatic removal and disinfection of bacterial biofilms. Appl. Environ. Microbiol. 63: 3724-3728.
• Kairo S.K., J. Bedwell, PC. Tyler, A. Carter and M.J. Corbel. 1999. Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines. Vaccine. 17: 2423-2428.
• Kaplan J.B., C. Ragunath, K. Velliyagounder, D.H. Fine and N. Ramasubbu. 2004. Enzymatic detachment of Staphylococcus epidermidis biofilms. Antimicrob. Agents Chemother. 48: 2633-2636.
• Kiri N., G. Archer and M.W. Climo. 2002. Combinations of lysostaphin with P-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 46: 2017-2020.
• Kokai-Kun J.F., S.M. Walsh, T. Chanturiya and J.J. Mond. 2003. Lysostaphin cream erdicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother. 47: 1589-1597.
• Lewis K. 2001. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45: 999-1007.
• Lindsay J.A. and M.T.G. Hoiden. 2004. Staphylococcus aureus: superbug, supergenome? Trends Microbiol. 12:378-385.
• Mack D., P. Becker, I. Chatterjee, S. Dobinsky, J.K.-M. Knobloch, G. Peters, H. Rohde and M. Herrmann. 2004. Mechanisms of biofilm formation in Staphylococcus epidermidis and Staphylococcus aureus: functional molecules, regulatory circuits, and adaptive responses. Int. J. Med. Microbiol. 294: 203-212.
• National Commitee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard fifth edition. M7-A5: 1-54.
• Patron R.L., M.W. Climo, B.P. Goldstein and G.L. Archer. 1999. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 43: 1754-1755.
• Prakash B., B.M. Veeregowda and G. Krishnappa. 2003. Biofilms: a survival strategy of bacteria. Curr. Sci. 85: 1299-1307.
• Sadowska B., M. Więckowska, W. Rudnicka and B. Różalska. 1998. Variation in slime/biofilm production by staphylococcal strains. AAM J. 7: 203-209.
• Von Eiff C, J.F. Kokai-Kun, K. Becker and G. Peters. 2003. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob. Agents Chemother. 47: 3613-3615.
• Vuong C. and M. Otto. 2002. Staphylococcus epidermidis infections. Microb. Infect. 4: 481-489.
• Wu J.A., C. Kusuma, J.J. Mond and J.F. Kokai-Kun. 2003. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob. Agents Chemother. 47: 3407.